Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Update

Universe Pharmaceuticals INC (NASDAQ:UPC) was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 11,506 shares, an increase of 1,406.0% from the April 30th total of 764 shares. Based on an average daily volume of 22,039 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.8% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Universe Pharmaceuticals Trading Up 5.6%

UPC stock opened at $2.76 on Thursday. Universe Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $11.00. The firm has a fifty day moving average price of $2.84 and a two-hundred day moving average price of $3.39.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.